Personalised treatment for cognitive impairment in dementia: development and validation of an artificial intelligence model

Personalised treatment for cognitive impairment in dementia: development and validation of an artificial intelligence model

Abstract Background Donepezil, galantamine, rivastigmine and memantine are potentially effective interventions for cognitive impairment in dementia, but the use of these drugs has not been personalised to individual patients yet. We examined whether artificial intelligence-based recommendations can...

Full description

Bibliographic Details
Main Authors: Qiang Liu, Nemanja Vaci, Ivan Koychev, Andrey Kormilitzin, Zhenpeng Li, Andrea Cipriani, Alejo Nevado-Holgado
Format: Article
Language:English
Published: BMC 2022-02-01
Series:BMC Medicine
Subjects:
Dementia
Personalised treatment
Acetylcholinesterase inhibitor
Memantine
Artificial intelligence
Online Access:https://doi.org/10.1186/s12916-022-02250-2

Internet

https://doi.org/10.1186/s12916-022-02250-2

Similar Items